Increase in Bloodstream Infection Due to Vancomycin-Susceptible Enterococcus faecium in Cancer Patients: Risk Factors, Molecular Epidemiology and Outcomes

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Gudiol, Carlota ^a,c   Ayats, Josefina ^a,d   Camoez, Mariana ^a,c   Domínguez, M Ángeles ^a,c   García Vidal, Carolina ^a,c   Bodro, Marta ^a,c   Ardanuy, Carmen ^a,d   Obed, Mora ^a   Arnan, Montserrat ^b   Antonio, Maite ^b   Carratalà, Jordi ^a,c  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN; CIPROFLOXACIN; CORTICOSTEROID; GENTAMICIN; POLYPEPTIDE ANTIBIOTIC AGENT; QUINOLINE DERIVED ANTIINFECTIVE AGENT; STREPTOMYCIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BLOODSTREAM INFECTION; CANCER PATIENT; ENTEROCOCCUS FAECIUM; FATALITY; FEMALE; GENOTYPE; HEALTH CARE QUALITY; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; MOLECULAR EPIDEMIOLOGY; NONHUMAN; OBSERVATIONAL STUDY; PROGNOSIS; PROSPECTIVE STUDY; RISK FACTOR;

ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; ENTEROCOCCUS FAECIUM; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTILOCUS SEQUENCE TYPING; NEOPLASMS; PATIENT OUTCOME ASSESSMENT; PROSPECTIVE STUDIES; RISK FACTORS; VANCOMYCIN; YOUNG ADULT;

EID: 84884372723     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074734     Document Type: Article

References (35)

1. Arias CA, Murray BE, (2012) The rise of the Enterococcus: beyond vancomycin resistance. Nat Rev Microbiol 10: 266-278. doi:10.1038/nrmicro2761. PubMed: 22421879.
2. Werner G, Coque TM, Hammerum AM, Hope R, Hryniewicz W, et al. (2008) Emergence and spread of vancomycin resistance among enterococci in Europe. Euro Surveill 13(47):p: ii=19046. PubMed: 19021959.
3. Willems RJL, van Schaik W, (2009) Transition of Enterococcus faecium from commensal organism to nosocomial pathogen. Future Microbiol 4: 1125-1135. doi:10.2217/fmb.09.82. PubMed: 19895216.
4. Rice LB, Carias L, Rudin S, Vael C, Goossens H, et al. (2003) A potential virulence gene, hylEfm, predominates in Enterococcus faecium of clinical origin. J Infect Dis 187: 508-512. doi:10.1086/367711. PubMed: 12552437.
5. Freitas AR, Tedim AP, Novais C, Ruiz-Garbajosa P, Werner G, et al. (2010) Global spread of the hylEfm colonization-virulence gene in megaplasmids of the Enterococcus faecium CC17 polyclonal subcluster. Antimicrob Agents Chemother 54: 2660-2665. doi:10.1128/AAC.00134-10. PubMed: 20385861.
6. Willems RJL, Top J, van Schaik W, Leavis H, Bonten M, et al. (2012) Restricted gene flow among hospital subpopulations of Enterococcus faecium. mBio 3: e00151-12. PubMed: 22807567.
7. McBride SJ, Upton A, Roberts SA, (2010) Clinical characteristics and outcomes of patients with vancomycin-susceptible Enterococcus faecalis and Enterococcus faecium bacteremia: a five-year retrospective study. Eur J Clin Microbiol Infect Dis 29: 107-114. doi:10.1007/s10096-009-0830-5. PubMed: 19916034.
8. Suppola JP, Kuikka A, Vaara M, Valtonen VV, (1998) Comparison of risk factors and outcome in patients with Enterococcus faecalis vs Enterococcus faecium bacteremia. Scand J Infect Dis 30: 153-157. doi:10.1080/003655498750003546. PubMed: 9730302.
9. Fortún J, Coque TM, Martín-Dávila P, Moreno L, Cantón R, et al. (2002) Risk factors associated with ampicillin-resistance in patients with bacteremia caused by Enterococcus faecium. J Antimicrob Chemother 50: 1003-1009. doi:10.1093/jac/dkf216. PubMed: 12461024.
10. Ghanem G, Hachem R, Jiang Y, Chemaly RF, Raad I, (2007) Outcomes for and risk factors associated with vancomycin-resistant Enterococcus faecalis and vancomycin-resistant Enterococcus faecium bacteremia in cancer patients. Infect Control Hosp Epidemiol 28: 1054-1059. doi:10.1086/519932. PubMed: 17932826.
11. Conde-Estévez D, Grau S, Albanell J, Terradas R, Salvadó M, et al. (2011) Clinical characteristics and outcomes of patients with vancomycin-susceptible Enterococcus faecalis and Enterococcus faecium bacteremia in cancer patients. Eur J Clin Microbiol Infect Dis 30: 103-108. doi:10.1007/s10096-010-1029-5. PubMed: 20711795.
12. Martínez-Odriozola P, Muñoz-Sánchez J, Gutiérrez-Macías A, Arriola-Martínez P, Montero-Aparicio E, et al. (2007) Análisis de 182 episodios de bacteriemia por enterococo: estudio de la epidemiología, microbiología y evolución clínica. Enfer Infecc Microbiol Clin 25: 503-507. doi:10.1157/13109986.
13. Treitman AN, Yarnold PR, Warren J, Noskin GA, (2005) Emerging incidence of Enterococcus faecium among hospital isolates (1993 to 2002). J Clin Microbiol 43: 462-463. doi:10.1128/JCM.43.1.462-463.2005. PubMed: 15635016.
14. Todeschini G, Tecchio C, Borghero C, D'Emilio A, Pegoraro E, et al. (2006) Association between Enterococcus bacteremia and death in neutropenic patients with haematological malignancies. J Infect 53: 266-273. doi:10.1016/j.jinf.2005.11.012. PubMed: 16388852.
15. DiazGranados CA, Jernigan JA, (2005) Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal infection. Clin Infect Dis 191: 588-595.
16. Noskin GA, Peterson LR, Warren JR, (1995) Enterococcus faecium and Enterococcus faecalis bacteremia: acquisition and outcome. Clin Infect Dis 20: 296-301. doi:10.1093/clinids/20.2.296. PubMed: 7742433.
17. Clinical and Laboratory Standards Institute (2010). erformance standards for antimicrobial susceptibility testing; 20th Informational Supplement. CLSI Document M100-S20. Wayne, PA: Clinical and Laboratory Standards Institute.
18. Coque TM, Willems RJ, Fortún J, Top J, Diz S, et al. (2005) Population structure of Enterococcus faecium causing bacteremia in a Spanish university hospital: setting the scene for a future increase in vancomycin resistance? Antimicrob Agents Chemother 49: 2693-2700. doi:10.1128/AAC.49.7.2693-2700.2005. PubMed: 15980338.
19. van Belkum A, Tassios PT, Dijkshoorn L, Haeggman S, Cookson B, et al. (2007) Guidelines for the validation and application of typing methods for use in bacterial epidemiology. Clin Microbiol Infect 13 (Suppl 3):: 1-46. doi:10.1111/j.1469-0691.2007.01723.x. PubMed: 17716294.
20. Homan WL, Tribe D, Poznanski S, Li M, Hogg G, et al. (2002) Multilocus sequence typing scheme for Enterococcus faecium. J Clin Microbiol 40: 1963-1971. doi:10.1128/JCM.40.6.1963-1971.2002. PubMed: 12037049.
21. Hosmer DW, Lemeshow S, (2000) Logistic regression: variable selection. In: Hosmer DW, Lemeshow S, eds. Applied logistic regression. 2nd ed. New York, NY: John Willey & Sons.
22. Cherif H, Kronvall G, Björkholm M, Kalin M, (2003) Bacteremia in hospitalised patients with malignant blood disorders: a retrospective study of causative agents and their resistance profiles during a 14-year period without antibacterial prophylaxis. Hematol J 4: 420-426. doi:10.1038/sj.thj.6200334. PubMed: 14671614.
23. Pan SC, Wang JT, Chen YC, Chang YY, Chen ML, et al. (2012) Incidence of andrisk factorsfor infection or colonization ofvancomycin-resistantenterococci in patients in the intensive care unit. PLOS ONE 7: e47297. doi:10.1371/journal.pone.0047297. PubMed: 23071778.
24. Almyroudis NG, Lesse AJ, Hahn T, Samonis G, Hazamy PA, et al. (2011) Molecular epidemiology andrisk factorsfor colonization byvancomycin-resistantEnterococcusin patients with hematologic malignancies. Infect Control Hosp Epidemiol 32: 490-496. doi:10.1086/659408. PubMed: 21515980.
25. Boyce JM, Opal SM, Potter-Bynoe G, LaForge RG, Zervos MJ, et al. (1992) Emergence and nosocomial transmission of ampicillin-resistant enterococci. Antimicrob Agents Chemother 36: 1032-1039. doi:10.1128/AAC.36.5.1032. PubMed: 1510390.
26. Gudiol C, Calatayud L, Garcia-Vidal C, Lora-Tamayo J, Cisnal M, et al. (2010) Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 65: 333-341. doi:10.1093/jac/dkp411. PubMed: 19959544.
27. Rice LB, (2001) Emergence of vancomycin-resistant enterococci. Emerg Infect Dis 7: 183-187. doi:10.3201/eid0702.010205. PubMed: 11294702.
28. Top J, Willems R, van der Velden S, Asbroek M, Bonten M, (2008) Emergence of clinal complex 17 Enterococcus faecium in the Netherlands. J Clin Microbiol 46: 214-219. doi:10.1128/JCM.01351-07. PubMed: 17977983.
29. Garbutt JM, Ventrapragrada M, Littenberg B, Mundy LM, (2000) Association between resistance to vancomycin and deaths in cases of Enterococcus faecium bacteraemia. Clin Infect Dis 30: 46.
30. Mundy LM, Sahm DF, Gilmore M, (2000) Relationships between enterococcal virulence and antimicrobial resistance. Clin Microbiol Rev 13: 513-522. doi:10.1128/CMR.13.4.513-522.2000. PubMed: 11023953.
31. Arduino RC, Jacques-Palaz K, Murray BE, Rakita RM, (1994) Resistance of Enterococcus faecium to neutrophil-mediated phagocytosis. Infect Immun 62: 5587-5594. PubMed: 7960141.
32. DiazGranados CA, Zimmer SM, Klein M, Jernigan JA, (2005) Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 41: 327-333. doi:10.1086/430909. PubMed: 16007529.
33. Arias CA, Murray BE, (2008) Emergence and management of drug-resistant enterococcal infections. Expert Rev Anti Infect Ther 6: 637-655. doi:10.1586/14787210.6.5.637. PubMed: 18847403.
34. Mishra NN, Bayer AS, Tran TT, Shamoo Y, Mileykovskaya E, et al. (2012) Daptomycin resistance in enterococci is associated with distinct alterations of cell membrane phospholipid content. PLOS ONE 7: e43958. doi:10.1371/journal.pone.0043958. PubMed: 22952824.
35. Prystowsky J, Siddiqui F, Chosay J, Shinabarger DL, Millichap J, et al. (2001) Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci. Antimicrob Agents Chemother 45: 2154-2156. doi:10.1128/AAC.45.7.2154-2156.2001. PubMed: 11408243.